This article is more than 5 years old. Information may no longer be current.

Alcon acquires PowerVision

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Alcon has acquired PowerVision, the developer of fluid-based IOLs for cataract surgery patients, according to a press release.

PowerVision’s presbyopia-correcting monofocal lens, which uses the eye’s natural accommodating response to transport fluid in the IOL, allows patients to actively focus on objects. Commercial availability of the IOL will be determined after additional development and clinical trials, the release said.

“As the industry leader in cataract surgery, we’re eager to accelerate development of this potentially breakthrough accommodating lens technology,” Michael Onuscheck, Alcon’s president of global business and innovation, said in the release. “By treating cataracts and restoring natural, continuous range of vision, this intraocular lens may be the preferred IOL for cataract surgery patients who desire spectacle independence.”

Alcon paid $285 million to PowerVision in the acquisition agreement, with additional milestone payments beginning in 2023.